Fluconazole Plus Cyclosporine: a Fungicidal Combination Effective Against Experimental Endocarditis Due to Candida Albicans

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Oct 19

PMID 11036003

Citations 54

Authors

O Marchetti

J M Entenza

D Sanglard

J Bille

M P Glauser

P Moreillon

Affiliations

Soon will be listed here.

Abstract

Recent observations demonstrated that fluconazole plus cyclosporine (Cy) synergistically killed Candida albicans in vitro. This combination was tested in rats with C. albicans experimental endocarditis. The MICs of fluconazole and Cy for the test organism were 0.25 and >10 mg/liter, respectively. Rats were treated for 5 days with either Cy, amphotericin B, fluconazole, or fluconazole-Cy. Although used at high doses, the peak concentrations of fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the kidneys. However, only the kidneys displayed concomitant polymorphonuclear infiltration. The therapeutic results reflected this dissociation. In the vegetations, only the fungicidal fluconazole-Cy combination significantly decreased fungal densities compared to all groups, including amphotericin B (P < 0.0001). In the kidneys, all regimens except the Cy regimen were effective, but fluconazole-Cy remained superior to amphotericin B and fluconazole alone in sterilizing the organs (P < 0.0001). While the mechanism responsible for the fluconazole-Cy interaction is hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.

Citing Articles

Calcineurin-dependent contributions to fitness in the opportunistic pathogen .

Pavesic M, Gale A, Nickels T, Harrington A, Bussey M, Cunningham K mSphere. 2024; 9(1):e0055423.

PMID: 38171022 PMC: 10826367. DOI: 10.1128/msphere.00554-23.

A Calcineurin Regulator MoRCN1 Is Important for Asexual Development, Stress Response, and Plant Infection of .

Liu C, Liu T, Lv Z, Qin M, Qu Z, Zhang Z Front Plant Sci. 2022; 13:925645.

PMID: 35783935 PMC: 9244802. DOI: 10.3389/fpls.2022.925645.

Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.

Murphy S, Bicanic T Front Cell Infect Microbiol. 2021; 11:759408.

PMID: 34970504 PMC: 8713075. DOI: 10.3389/fcimb.2021.759408.

Drug repurposing strategies in the development of potential antifungal agents.

Zhang Q, Liu F, Zeng M, Mao Y, Song Z Appl Microbiol Biotechnol. 2021; 105(13):5259-5279.

PMID: 34151414 PMC: 8214983. DOI: 10.1007/s00253-021-11407-7.

The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na/H Exchangers.

Vu K, Blumwald E, Gelli A Front Microbiol. 2021; 12:673035.

PMID: 34025629 PMC: 8133316. DOI: 10.3389/fmicb.2021.673035.

References

Higgins C . ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992; 8:67-113. DOI: 10.1146/annurev.cb.08.110192.000435. View

Louie A, Liu Q, Drusano G, Liu W, Mayers M, Anaissie E . Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother. 1998; 42(6):1512-4. PMC: 105634. DOI: 10.1128/AAC.42.6.1512. View

Fonzi W, Irwin M . Isogenic strain construction and gene mapping in Candida albicans. Genetics. 1993; 134(3):717-28. PMC: 1205510. DOI: 10.1093/genetics/134.3.717. View

Witt M, Imhoff T, Li C, Bayer A . Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains. Antimicrob Agents Chemother. 1993; 37(9):2030-2. PMC: 188117. DOI: 10.1128/AAC.37.9.2030. View

Rex J, Bennett J, Sugar A, Pappas P, van der Horst C, Edwards J . A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994; 331(20):1325-30. DOI: 10.1056/NEJM199411173312001. View

Anaissie E, Kontoyiannis D, Huls C, Vartivarian S, Karl C, Prince R . Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis. 1995; 172(2):599-602. DOI: 10.1093/infdis/172.2.599. View

Garcha U, Brummer E, Stevens D . Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species. J Infect Dis. 1995; 172(6):1620-3. DOI: 10.1093/infdis/172.6.1620. View

Sanglard D, Kuchler K, Ischer F, Pagani J, Monod M, Bille J . Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother. 1995; 39(11):2378-86. PMC: 162951. DOI: 10.1128/AAC.39.11.2378. View

List A . Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996; 10(6):937-42. View

10.

Nguyen M, Peacock Jr J, Morris A, Tanner D, Nguyen M, Snydman D . The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100(6):617-23. DOI: 10.1016/s0002-9343(95)00010-0. View

11.

Chemlal K, Joly V, Farinotti R, Seta N, Yeni P, Carbon C . Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother. 1996; 40(1):263-6. PMC: 163098. DOI: 10.1128/AAC.40.1.263. View

12.

Ho S, Clipstone N, Timmermann L, Northrop J, GRAEF I, Fiorentino D . The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996; 80(3 Pt 2):S40-5. DOI: 10.1006/clin.1996.0140. View

13.

Sanglard D, Ischer F, Monod M, Bille J . Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother. 1996; 40(10):2300-5. PMC: 163524. DOI: 10.1128/AAC.40.10.2300. View

14.

Sanglard D, Ischer F, Monod M, Bille J . Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (Reading). 1997; 143 ( Pt 2):405-416. DOI: 10.1099/00221287-143-2-405. View

15.

Del Poeta M, Cruz M, Cardenas M, Perfect J, Heitman J . Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(3):739-46. PMC: 89756. DOI: 10.1128/AAC.44.3.739-746.2000. View

16.

Marchetti O, Moreillon P, Glauser M, Bille J, Sanglard D . Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother. 2000; 44(9):2373-81. PMC: 90072. DOI: 10.1128/AAC.44.9.2373-2381.2000. View

17.

Fields Jr B, Bates J, Abernathy R . Amphotericin B serum concentrations during therapy. Appl Microbiol. 1970; 19(6):955-9. PMC: 376832. DOI: 10.1128/am.19.6.955-959.1970. View

18.

Rubinstein E, Noriega E, Simberkoff M, Rahal Jr J . Tissue penetration of amphotericin B in Candida endocarditis. Chest. 1974; 66(4):376-7. DOI: 10.1378/chest.66.4.376. View

19.

Calderone R, Rotondo M, Sande M . Candida albicans endocarditis: ultrastructural studies of vegetation formation. Infect Immun. 1978; 20(1):279-89. PMC: 421584. DOI: 10.1128/iai.20.1.279-289.1978. View

20.

Heraief E, Glauser M, FREEDMAN L . Natural history of aortic valve endocarditis in rats. Infect Immun. 1982; 37(1):127-31. PMC: 347499. DOI: 10.1128/iai.37.1.127-131.1982. View